Integrated drug discovery Charnwood Discovery is now part of Concept Life Sciences after a late-2024 acquisition, creating a more integrated drug discovery offering. This presents a sales opportunity to upsell end-to-end CRO services and expanded collaboration across preclinical to early development.

Small to mid-size focus With 11-50 employees and revenue under one million, the company operates with a lean footprint. Targeted partnerships and scalable collaboration models could be appealing, offering flexible engagement options and advisory services to expand capacity without significant fixed costs.

DMPK and PROTAC capabilities Past leadership changes in DMPK and historical focus on PROTAC development indicate strength in metabolism and targeted protein degradation. Opportunities exist to cross-sell DMPK optimization, PROTAC chemistry support, and assay development to broader CLS clients.

Strategic partnerships Existing and past collaborations, including partnerships with Awakn Life Sciences and integration with CLS, suggest receptiveness to alliance-based models. Propose co-development projects, shared IP ventures, and joint marketing to capture early-stage therapeutic programs.

Global CLS ecosystem As part of Concept Life Sciences, Charnwood Discovery can leverage CLS’s global reach, marketing, and client base to access new pharma/biotech pipelines. Focus outreach on CLS’s integrated services to drive cross-sell of discovery, analytics, and manufacturing capabilities.